Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

NCT03064074 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Osteogenesis Imperfecta

Interventions

DRUG: Fresolimumab

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]